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The beginning
Scientific publishing began thousands of years ago when the 
Greek philosophers started to write books about the creation of 
the world and the position of humans in it. Initially, philosophical 
thoughts and scientific concepts and discoveries were published 
in books and only much later in papers. Scientific journals, in the 
proper sense, are more recent and were developed in the seven-
teenth and eighteenth centuries. Since then, the number of scien-
tific journals has increased tremendously with an ever increasing 
number of journals appearing worldwide publishing over 2.5 mil-
lion papers annually. Indeed, it is anticipated that, with the rise in 
research in China and India, the number of scientific journals and, 
as a consequence, of scientific publications will increase further.
What is good scientific publishing?
The major principles of good scientific publishing are: (1) honesty, 
(2) precision, (3) novelty,  (4) stringency and (5) timing (Table 1).
Scientific findings should obviously be reported exactly how they
were obtained1. Only honestly reported findings will survive the 
test of time and will not be falsified by later publications2. Indeed, 
the truth of scientific discovery is mainly determined by conjec-
tures and refutations, as Sir Karl Popper put it, rather than the cur-
rently hotly debated conflicts of interest3.
Table 1. Major principles of good scientific publishing.
Item Requirements
Honesty Report only what has been measured as it has 
been measured. Be aware of the limitations of 
your study
Precision Use state-of-the-art tools, report numbers with 
range and deviations, provide proper statistical 
analysis
Novelty Check PubMed on what has been previously 
published, focus on incremental and/or true 
novelty of findings
Stringency Write clearly and logically
Timing Be in time, only timely findings can be novel
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Precision is another principle of science, as it is – contrary to 
theology and philosophy – quantitative in nature. Scientific papers 
primarily report measured parameters, their mean values and 
standard deviations and a statistical analysis of the obtained num-
bers that support or disprove a preconceived hypothesis. Today, 
not a single paper will be published in respected journals without 
a proper statistical review.
Then, novelty is a crucial element, as only novel findings 
deserve to be published; science stands for progress and progress 
requires novelty. Certainly, confirmation (or rather lack of falsi-
fication, if we follow Sir Karl Popper) is equally important, but 
this should be done with novel insights and/or larger numbers, 
respectively. Nevertheless, the third and fourth confirmation will 
not make it into a prime journal and the rest should not even be 
published at all.
Furthermore, scientific papers must be convincing. Only strin-
gent arguments in the discussion section will convince review-
ers and editors that the findings deserve publication. As Ludwig 
Wittgenstein put it, “What can be said at all, can be said clearly”4. 
The discussion of a paper should provide a logical flow of argu-
ments and focus on the results of the study and not on speculation.
Finally, timing is crucial, as competition has never been as 
fierce as it is now. Of note, most scientists who ever worked in 
history work today. Thus, with declining acceptance rates in most 
first-line journals, the life of most scientists becomes increasingly 
stressful.
The peer review system
While ancient writers published their work as it was written in the 
first place, in the Middle Ages the Catholic Church censored any 
publication or authors self-censored their thoughts and writings to 
avoid any deviation from canonical teaching. The aims of peer 
review, however, are completely different and historically much 
more recent. Peer review was introduced to help readers to obtain 
the best information according to the aforementioned criteria. 
Henry Oldenburg (1618-1677) is considered the inventor of peer 
review during his time as secretary of the Royal Society5. When 
he was an editor of the Philosophical Transactions he felt uncom-
fortable as a theologist to assess the quality of submitted papers 
from different areas of science and medicine. He therefore relied 
on the judgement of colleagues of standing in fields other than his 
own. As such, he invented the peer. A peer is an individual, if we 
follow the definition of the American College Dictionary, of the 
same civil rank or scientific standing as the author of the submit-
ted work, an equal before the law. This has remained as such ever 
since, and even today we select peers with a particular reputa-
tion, experience and standing in a given field to assess submitted 
papers. However, in contrast to the medieval censorship, the peer 
review system does not intend to suppress thoughts or findings, 
but rather to improve the quality of submitted work thanks to sug-
gestions of expert peers and more recently statistical reviewers.
The question is: how perfect is peer review? Many disap-
pointed authors whose work has been rejected are critical of peer 
review. However, although peer review might not be perfect, it 
certainly improves the quality of submitted papers that make the 
bar of a particular journal. Indeed, reviewers are asked to assess 
methods, the statistics and data and whether the conclusions are 
supported by the results. Papers of interest that are revised after 
constructive review are certainly better than the original version. 
Thus, although peer review may have overlooked some unusual 
or even innovative findings, overall it does provide a service to 
authors and to science at large – nothing is perfect, nor is peer 
review, but it certainly fosters reliable scientific reporting.
Will this system survive in the future? Most scientists would 
agree that peer review is here to stay and distinguishes high-qual-
ity journals from the rest of the crowd. Indeed, a lot of low-quality 
and in particular open access journals do not provide proper peer 
review and many cannot even afford state-of-the-art statistical 
reviewing with their business model. Nevertheless, as Churchill 
stated for democracy (in his speech to the House of Commons 
on November 11, 1947), peer review may be imperfect, but we 
do not yet know of any better system. And indeed it is necessary: 
who could read the thousands of papers published today? What is 
more, it is a service to readers in order to provide publications of 
certified high quality.
Journal rating
Humans love to compete: this starts in school and is the main 
attractiveness of competitive sports – we want to know who the 
winner is. Scientists are no different: we have citation indices, the 
h-index for researchers and various impact factors for journals. In 
particular, the altmetric score introduced a completely new aspect, 
i.e., the impact a paper has in social media, newspapers and blogs. 
Hence, for some papers the altmetric score may be huge, but cita-
tions in the scientific literature low or vice versa. Indeed, altmetric 
scores are particularly high for findings on emotional topics, diet 
and nutrition, environment among others. Thus, they all measure 
a different aspect of science – in short, they measure the unmeas-
urable6. Whatever these ratings measure, they are highly influen-
tial: they determine the visibility and reputation of scientists and 
journals, and they are important in academic promotion and not 
least for the self-esteem of editors and authors. There is no ques-
tion about it – they are here to stay. We may argue which of the 
factors is most important, but in the end we all want them and will 
also want to use them in the future.
Changing environment
Over the last few decades scientific publishing has changed con-
siderably due to cultural, logistic, technical and political factors:
(1) The internet has changed our life. Thirty years ago this 
year, Sir Tim Berners-Lee came up with the idea of join-
ing up hypertext with the early Internet of the time, creat-
ing a system for sharing and distributing information not just 
within a company, but globally. He named it the World Wide 
Web. Since then, the world wide web has had an unfore-
seen influence on our culture, on business and technology 
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by providing near-instant communication by electronic mail, 
voice transmissions, video conferencing and online shopping. 
As a consequence, the flow of information has been dramati-
cally accelerated and expanded with discussion fora, blogs 
and numerous social media products. In science and beyond, 
growing amounts of data are transmitted at higher and higher 
speed. The electronic platform of journals has become more 
important than the printed version. Indeed, the European Heart 
Journal alone enjoys around 10 million downloads per year 
from its platform.
(2) The speed of discovery is continously accelerating. As an 
example, the discovery of gain-of-function and loss-of-func-
tion mutations of the PCSK9 gene in 20037 led in less than 
a decade to novel drugs, the PCSK9 inhibitors8 and 14 years 
later to proof of their efficacy on clinical outcomes9 – a true 
record in research and development. In contrast, it took dec-
ades from the discovery of Mycobacterium tuberculosis by 
Robert Koch in 188210 to the proof of an effective treatment 
in the seminal streptomycin trial by Austin Bradford Hill in 
194811. With the ever increasing number of scientists working 
worldwide, due largely to China and India, speed – and in turn 
competition – will increase further.
(3) The expectations of readers, reviewers and editors fly higher 
and higher. Indeed, while years ago it was sufficient to report 
an interesting finding, today reviewers and editors expect in-
depth characterisation of molecular pathways. Randomised 
studies carry more weight than registries and larger and larger 
patient populations are expected in order to support the claims 
of a paper. Big data, machine learning12-14 and artificial intel-
ligence15 will change science and medicine further.
(4) The reading behaviour of the new generation has changed as 
well. Today’s young readers are less prepared to read long 
texts and expect more visual content. Indeed, not only have 
papers become shorter over the last few decades, but they are 
also more extensively illustrated with tables and figures as 
well as supplemental files. Some journals now also provide 
videos or even online lectures of their papers and interviews 
with prominent scientists.
(5) The conflict of interest policy has also affected publishing. 
Although pharmaceutical and device industries have made 
important contributions to the progress of medicine at large 
and cardiology in particular, their involvement is increasingly 
seen as a problem affecting unbiased data reporting. Similarly, 
the trustworthiness of authors working with industry has 
increasingly been brought into question, mainly by media, but 
also by the public at large16. To address this, many societies 
have produced standards to handle the issue – with moderate 
success17.
(6) The business model of publishing is also under scrutiny. While 
most prestigious journals publish using the subscription model 
where the reader, or his/her institution, pays for access to con-
tent, an increasing number of journals use the open access sys-
tem. Open access is a new business model where the author 
pays, while the reader gets free access to published articles. 
In principle, although this is not the rule, open access allows 
proper peer review; it is primarily a different business model. 
In addition, there are hybrid journals such as the European 
Heart Journal among many others, where selected papers are 
the “editor’s choice”, i.e., they are freely accessible, while the 
rest can only be downloaded by subscribers. However, in most 
journals, authors who wish to have their article published with 
open access may pay for that, if they wish to do so.
Is speed quality?
In the age of the internet, speed has become a quality factor in 
its own right. Indeed, some even announced the end of jour-
nals as they would be too slow in reporting the progress of sci-
ence18. However, whether new forms of digital publishing would 
be faster and better than today’s peer-reviewed journals remains 
unproven. To speed up publishing further, prepublication has been 
proposed19 or even declared mandatory. Many journals are now 
accepting work that has been made public on an institutional plat-
form, and some proponents of this strategy have even suggested 
making every version of the manuscript available. This, however, 
has several downsides: first, it produces a number of, potentially 
differing, revised versions of a manuscript with in some cases 
even differing conclusions. Secondly, this will create confusion 
and may even damage the credibility of science among the pub-
lic at large. Third, who will have the time to read up to five ver-
sions of a single manuscript at a time when 50 million articles are 
available since the inception of science? Finally, is speed a quality 
marker of science or is it rather reproducibility of content? It took 
William Harvey years to produce De Motu Cordis, but it made 
history20; stem cell research developed exceedingly fast and ended 
up in a scandal. The lesson is: good scientific publishing requires 
time and we should allow for that.
Certainly, there is a sweet spot: we should not follow the exam-
ple of the dark lady of DNA. Indeed, Rosalind Franklin made 
groundbreaking discoveries on the structure of DNA, but was shy 
of publishing them21. When a certain James Watson visited her lab 
and showed extreme interest in her radiographs, she ended up in 
the footnote of a landmark paper where it reads, “We have also 
been stimulated by … the unpublished experimental results and 
ideas of … Dr. R. E. Franklin”22.
Plan S
The discussion over whether subscription or open access is the 
right way to publish has heated up with the presentation of the 
Plan S in 201823. It all started with the recognition that publishing 
companies make astonishing profits by publishing findings they 
do not pay for, but have been supported by charities and foun-
dations, federal institutions and by researchers working for free. 
For instance, Elsevier, one of the largest publishing companies, 
apparently makes several hundred millions of dollars profit every 
year. Understandably, this has led to a lot of criticism by scien-
tists, governmental agencies and the media. As a consequence, an 
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increasing number of funding bodies are supporting the so-called 
Plan S which is also supported by the European Commission and 
the European Research Council (ERC). Plan S aims to change the 
system of scientific publishing completely to open access (https://
www.coalition-s.org/why-plan-s/). Importantly, Plan S does not 
allow the hybrid model discussed above, but intends to force sci-
entific journals to publish only open access as of 2020 (Table 2).
What are the advantages and disadvantages of open access 
publishing? Basically, the two models are different business 
models: in the subscription model the reader pays, while with 
open access the author pays (Table 2). But there is more to it: the 
Budapest Open Access Initiative (BOAI) published in 2002 took 
the position that all scientists and scholars should publish their 
research in journals without payment on internet platforms to 
allow rapid and unrestricted dissemination of their results to the 
community at large. So, the primary argument for open access is 
dissemination – certainly something that most would agree with. 
Secondly, the enormous profits of publishing companies fostered 
the determination of open access enthusiasts to recommend only 
this way of publishing and not any other. Indeed, the enormous 
profits of publishing companies are a foreign body in academic 
life.
Four major questions remain unanswered that need to be con-
sidered. (1) Is open access living up to its promises? (2) Is the 
quality equal to that of subscription publishing? (3) Is it affordable 
for scientists from less affluent countries? (4) Could it lead to new 
conficts of interest for editors and publishers?
(1) Is open access more effective in terms of dissemination? 
Obviously, this is not easy to measure, particularly since first-
line subscription and hybrid journals such as the New England 
Journal of Medicine and the European Heart Journal among 
others have millions of downloads from their platform every 
year reflecting massive dissemination. The same applies to 
citations: by far the best cited journals are those which publish 
using the subscription or hybrid model and not open access. 
Although the Budapest Open Access Initiative (BOAI) is 
17 years old, this has not changed much24. Indeed, in medicine 
and in cardiovascular medicine in particular, none of the open 
access journals has reached a sizeable impact: the Journal of 
the American Heart Association (JAHA) has an impact factor 
score of 5.117, PLOS ONE of 2.766 and ESC Heart Failure is 
still waiting to receive one – only PLOS Medicine stands out 
with an impact factor of 11.675.
(2) Does open access improve the quality of scientific publica-
tions? Proper peer review is a costly process. First, it requires 
a team of editorial managers handling manuscripts, checking 
format and overlap with published work and a team of com-
petent statistical reviewers (who, unlike content reviewers, do 
not work for free). Second, professional publishing requires an 
attractive platform with changing content, news section, links 
and movies. Third, a first-line journal needs a press officer, 
a social media officer and medical writers for the news sec-
tion. Finally, an ethics committee to handle issues of scientific 
malpractice should be standard. All of this has to be organised 
and coordinated by a sizeable editorial team – this requires an 
appropriate budget.
 Can all this be financed within an open access model? Yes, if 
the publication rate is high enough. High-quality peer review 
is costly and there is a limit for affordable registration fees that 
make running an open access journal at the prime journal level 
challenging.
(3) Who pays for open access publishing? The funding bodies sup-
porting open access have promised to provide resources to pay 
for publication rates – but how much will this be? Currently, 
1,500 to 3,000 euros is the cost of publishing a single paper. 
What if an unusually productive scientist publishes five papers 
per year? What if he/she works in a country with a less affluent 
economy where physicians’ salaries are in the range of 3,000 
euros or less? What if a paper gets rejected and the authors have 
to try two or three other journals to get published? Who will 
cover these costs? Yes, Plan S promises that funders will pay 
everything – almost a fairy tale (Table 2) – but is this credible? 
What about research paid by universities, by funders not signing 
up for Plan S? Undoubtably, this will lead to a further discrimi-
nation of countries that are desperately trying to develop their 
academic activities to the level of Western societies.
(4) Who loses with open access publishing? Currently, many 
journals are official organs of scientific societies such as the 
European Society of Cardiology, the American College of 
Cardiology and the American Heart Association. All these 
Table 2. Modified and shortened summary of the principles of 
plan S (Source: https://www.coalition-s.org/why-plan-s/).
– Authors retain copyright of their publication without restrictions
– All publications must be published under an open access
– The funders will establish the criteria and requirements for the 
services that compliant high-quality Open Access journals must 
provide
– If high-quality Open Access journals do not yet exist, the funders 
will, in a coordinated way, provide incentives to establish and 
support them
– Support will also be provided for Open Access infrastructures 
where necessary
– Open Access publication fees are covered by the funders or 
universities, not by individual researchers
– All scientists should be able to publish Open Access even if their 
institutions have limited means
– When Open Access fees are applied, their funding is standardised 
and capped across Europe
– The funders will ask universities, research organisations, and 
libraries to align their policies and strategies, notably to ensure 
transparency
– The ‘hybrid’ model of publishing is not compliant with the above 
principles
– The funders will monitor compliance and sanction 
non-compliance.
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societies receive considerable income from their published 
products that they reinvest in educational activities, grants 
for young scientists among others. A first estimate of these 
societies suggests that they will lose considerable income 
with open access compared to the current subscription model, 
something which will affect the medical community at large.
(5) A new conflict of interest. Finally, the open access system cre-
ates a new conflict of interest for publishers and editors alike 
as their profit and income will depend on how many papers 
they accept and how little they spend for a high-quality peer 
review process to select only high-quality papers. Most first-
line journals such as the New England Journal of Medicine, 
The Lancet or the European Heart Journal publish relatively 
few, but high-quality papers. They publish a large part of the 
1% most cited papers in their field because they rigorously 
select for quality and novelty and have acceptance rates of 
only 4 to 8%. Such quality selection is not optimally compat-
ible with an open access business model, but it certainly is 
a necessity in a world that is flooded with more than 100,000 
papers a year.
(6) Accessibility and dissemination. No doubt there are advan-
tages of open access publishing, the most important one being 
unrestricted accessibility of information for readers around 
the world. Therefore, newly gained knowledge should spread 
faster and more effectively compared to subscription journals. 
However, current data suggest only a small advantage for open 
access journals compared to subscription publishing25. This 
may be due to the fact that most open access journals lack high 
impact and reputation. Also, most first-line subscription journals 
run a hybrid model whereby some articles are open access (e.g., 
in the European Heart Journal usually two per issue) and open 
access can be purchased, if desired. Furthermore, all papers 
are made fully accessible after a period of time (e.g., usually 
12 months). Thus, hybrid publishing seems to be the model of 
choice. Not Plan S but “Plan B” should be the solution (Table 3).
Conclusions
Scientific publishing is at a turning point where we have to 
choose between speed and quality and have to take a position 
for or against Plan S. Quality must remain the gold standard and 
only proper peer review can ensure that. In the current flood 
of publications, prime journals provide a service as they select 
those papers that must be read. The current focus on maximal 
speed is toxic for science; we have to acknowledge that repro-
ducible scientific discovery requires time. Finally, dissemi-
nation of science is indeed important and should be fostered. 
However, rather than an ideological approach as Plan S pro-
poses, we should support flexible models of publishing as pro-
vided by hybrid journals and allow full open access for those 
who choose that path26.
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